

Drug patent ruling in favour of Teva

Washington: The US Supreme Court on Tuesday ruled for **Teva Pharmaceutical Industries Ltd** in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review. On a 7-2 vote, the justices said that the US court of appeals for the federal circuit had not used the correct approach in analysing whether the patent in question, due to expire in September 2015, was valid. As litigation continues, the legal confusion is likely to benefit Israel-based Teva. **REUTERS**

Patent